CAR Page

Unlike the conventional CAR-T cell technology that relies on the use of patient blood cells to generate highly personalized αβ T cell-based therapy for certain cancer, our CAR-γδ T cell technology enable the use of donor blood cells as starting materials to manufacture “off-the-shelf” therapy (CTM-N2D therapy) to target stress-induced cancer antigens for a wide spectrum of cancers for many patients.